Literature DB >> 17337768

Human tumor antigens, immunosurveillance, and cancer vaccines.

Olivera J Finn1.   

Abstract

Cancer is a serious health problem as well as a scientific challenge. A lot has been learned about the process of transformation of a normal cell into a tumor cell by studying genes and proteins that regulate this process either in cis or in trans. However, whether these molecular mechanisms succeed in fulfilling their potential to give a clinically evident disease depends in great measure on the host response to those molecular changes. The work of my laboratory aims to provide evidence in animal models as well as in cancer patients that immune system can control cancer growth and that this important function can be improved through vaccination with well-defined tumor antigens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17337768     DOI: 10.1385/IR:36:1:73

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  24 in total

1.  A decade in the life of tumor immunology.

Authors:  O J Finn; M T Lotze
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

2.  Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.

Authors:  M M Soares; V Mehta; O J Finn
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

3.  Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients.

Authors:  J Schmielau; M A Nalesnik; O J Finn
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

4.  Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53.

Authors:  Min Yu; Qimin Zhan; Olivera J Finn
Journal:  Mol Immunol       Date:  2002-05       Impact factor: 4.407

5.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

Authors:  D L Barnd; M S Lan; R S Metzgar; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

6.  The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells.

Authors:  E M Hiltbold; A M Vlad; P Ciborowski; S C Watkins; O J Finn
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

7.  T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.

Authors:  Hiroyuki Suzuki; Daniel F Graziano; John McKolanis; Olivera J Finn
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

8.  Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells.

Authors:  E M Hiltbold; P Ciborowski; O J Finn
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

9.  Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.

Authors:  Ramesh K Ramanathan; Kenneth M Lee; John McKolanis; Elizabeth Hitbold; Wolfgang Schraut; Arthur J Moser; Elizabeth Warnick; Theresa Whiteside; Jennifer Osborne; Hyoung Kim; Roger Day; Monica Troetschel; Olivera J Finn
Journal:  Cancer Immunol Immunother       Date:  2004-09-14       Impact factor: 6.968

10.  Premalignant lesions as targets for cancer vaccines.

Authors:  Olivera J Finn
Journal:  J Exp Med       Date:  2003-11-24       Impact factor: 14.307

View more
  12 in total

Review 1.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

2.  Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes.

Authors:  Anna Julia Wiecek; Daniel Hadar Jacobson; Wojciech Lason; Maria Secrier
Journal:  Front Cell Dev Biol       Date:  2021-07-09

Review 3.  Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art.

Authors:  Taylor H Schreiber; Luis Raez; Joseph D Rosenblatt; Eckhard R Podack
Journal:  Semin Immunol       Date:  2010-03-11       Impact factor: 11.130

Review 4.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

Review 5.  Dendritic cells: a critical player in cancer therapy?

Authors:  Anna Karolina Palucka; Hideki Ueno; Joseph Fay; Jacques Banchereau
Journal:  J Immunother       Date:  2008 Nov-Dec       Impact factor: 4.456

Review 6.  Anaplastic lymphoma kinase: an oncogene for tumor vaccination.

Authors:  Cristina Mastini; Cinzia Martinengo; Giorgio Inghirami; Roberto Chiarle
Journal:  J Mol Med (Berl)       Date:  2009-03-30       Impact factor: 4.599

7.  An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer.

Authors:  Kimberly R Kalli; Christopher J Krco; Lynn C Hartmann; Karin Goodman; Matthew J Maurer; Chao Yu; Elliot M Johnson; Courtney L Erskine; Mary L Disis; Peter J Wettstein; John D Fikes; Melanie Beebe; Glenn Ishioka; Keith L Knutson
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

8.  Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

Authors:  Qing Zhou; Christoph Bucher; Meghan E Munger; Steven L Highfill; Jakub Tolar; David H Munn; Bruce L Levine; Megan Riddle; Carl H June; Daniel A Vallera; Brenda J Weigel; Bruce R Blazar
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

9.  Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.

Authors:  S M Geary; C D Lemke; D M Lubaroff; A K Salem
Journal:  Cancer Immunol Immunother       Date:  2011-05-28       Impact factor: 6.630

10.  Immunity, ageing and cancer.

Authors:  Evelyna Derhovanessian; Rafael Solana; Anis Larbi; Graham Pawelec
Journal:  Immun Ageing       Date:  2008-09-24       Impact factor: 6.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.